Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, plans to report its Q1 2026 operating and financial results on Friday, May 15, 2026.
The press release will cover financial results for the quarter ended March 31, 2026 and provide updates on clinical trials and development of the company’s AI platforms.
Lantern Pharma (NASDAQ: LTRN) unveiled a development roadmap for withZeta.ai on May 7, 2026, adding ZetaSwarm™ (multi-agent swarm intelligence), ZetaOmics™ (real-time multi-omic bioinformatics), and enterprise-grade features. The platform is commercially available via subscription and is presented as a non-dilutive revenue stream.
Planned capabilities include 34-tool integration, real-time cohort analyses, coordinated specialist agents, org-level accounts, audit logs, private knowledge bases, and institutional deployment features.
Lantern Pharma (NASDAQ: LTRN) expanded predictBBB.ai into a real-time Large Quantitative Model (LQM) delivered as a web service for small-molecule developability profiling. By submitting a single SMILES string users get a 360-degree profile in seconds across 99 molecular features, with five algorithms ranking in the top 12 on the Therapeutic Data Commons leaderboard. The LQM is integrated into withZeta.ai, supports high-throughput screening, and is offered under a planned subscription roadmap with API access in development; Lantern is inviting early collaboration with pharma partners.
Lantern Pharma (NASDAQ: LTRN) will publicly demonstrate withZeta.ai, its multi‑agentic AI co‑scientist platform, on April 30, 2026 with two live sessions at 8:30 AM ET and 4:30 PM ET.
The platform, publicly shown after debuts at Nasdaq MarketSite and AACR 2026, executes real‑time multi‑database research workflows and offers subscription tiers aimed at rare cancer research and commercial users.
Lantern Pharma (NASDAQ: LTRN) scheduled a mid‑May 2026 Type C meeting with the FDA to seek protocol amendments to its Phase 2 HARMONIC trial of LP-300. Emerging data (cutoff April 13, 2026) show an 8.3‑month mPFS in EGFR Exon 21 L858R patients (n=16) with no added toxicity versus chemotherapy.
Lantern proposes focusing enrollment on L858R, converting to a Simon two‑stage single‑arm Phase 2, and increasing LP-300 cycles from 6 to 8 to further evaluate durability and safety.
Lantern Pharma (Nasdaq: LTRN) launched withZeta.ai, the world’s first multi-agentic AI co-scientist for rare cancer drug discovery, now available with introductory, academic, and commercial subscriptions.
Commercial subscriptions are live at withzeta.ai, with debut demos at Nasdaq MarketSite on April 16, 2026 and AACR 2026 (Booth 5054) April 17–22. The platform leverages Lantern’s RADR knowledge-base covering 438 cancer types, claims a PredictBBB.ai 94.1% accuracy, and builds on three drugs in clinical trials, >100 patients dosed, and 12 FDA designations.
Lantern Pharma (Nasdaq: LTRN) will host a live investor and analyst briefing on April 9, 2026 at 8:30 AM ET featuring a demonstration of withZeta.ai, a multi-agentic AI co-scientist for rare cancer drug discovery, development, and trial design.
The webcast will cover platform capabilities, commercial subscription model, competitive positioning, and near-term revenue strategy. Lantern cites 12 FDA designations, three drugs in precision oncology trials and over 100 patients dosed as part of the platform’s clinical heritage.
Lantern Pharma (NASDAQ: LTRN) reported 2025 operational and financial results, highlighting clinical progress across LP-300, LP-184, LP-284 and IND clearance for STAR-001, RADR® platform expansion and launch of withZeta.ai.
Key metrics: $10.1M cash at year-end, 48% LP-184 clinical benefit rate at therapeutic doses, LP-300 safety lead-in showing 86% clinical benefit and 43% objective response in initial U.S. patients.
Lantern Pharma (NASDAQ: LTRN) confirmed that Panna Sharma remains President, CEO, and director after a false third‑party article claimed he stepped down. The board affirmed confidence, cited a recently cleared IND for STAR-001 pediatric CNS trial, and warned of potential market manipulation while investigating and considering legal and regulatory referrals.
The company reiterated reliance on official SEC filings and its investor site and noted a webcast on March 30, 2026 at 4:30 p.m. ET to review FY2025 results.
Lantern Pharma (NASDAQ: LTRN) and Starlight Therapeutics announced FDA clearance of IND No. 179145 to initiate a planned Phase 1 pediatric CNS trial of STAR-001 (LP-184). The multicenter study will test STAR-001 as monotherapy and with spironolactone across relapsed/refractory ATRT, DIPG, GBM, medulloblastoma, and ependymoma, enrolling ~18–42 patients at POETIC sites. Preclinical data showed ERCC3 protein reduction ≥50% and a combination survival benefit (median 27 to 76 days, +181%, p=0.0018). Trial initiation is subject to additional funding.